PrintThe Burrill Report
The Burrill Report (September 16, 2013): Developing Vaccines for the Deadliest Diseases (.MP3,11.85 Mb)
Some of the world’s deadliest infectious diseases have proven difficult targets for vaccines, but the nonprofit Seattle BioMed is applying systems biology to develop new ways to halt their devastating effects. Such an approach has led to the development of an experimental malaria vaccines that’s showing promise in human clinical testing. We spoke to Stefan Kappe, professor at Seattle BioMed, about the research institute, the benefits of a systems biology approach, and what it will take to commercialize a malaria vaccine.
September 12, 2013
http://www.burrillreport.com/article-developing_vaccines_for_the_deadliest_diseases.html
VACCINES
Developing Vaccines for the Deadliest Diseases
Podcast: September 16, 2013[Please login to post comments]
- Why I Decided Not to Get Cancer
IOM study finds care in the United States is facing a crisis. Read More - Paying Docs for Performance Improves Outcomes
Incentivized care program produced better results in comparison to traditional fee-for-service arrangement. Read More - Theranos to Offer Lab Tests through Walgreens
Deal expands drugstore chain’s push to provide primary care services to consumers. Read More - Roche Will Develop Inovio’s Preclinical Cancer Vaccine
Pharma sees potential in combination with its pipeline candidates Read More - Lilly Brings $500M Arbitration Claim Against Canada
Action brought under NAFTA could have broad impacts on how intellectual property treaties are enforced. Read More - Gilead Seeks Approval for its First Cancer Therapy
Company files new drug application for first in a new class of treatment for non-Hodgkin's lymphoma. Read More - OvaScience Tussles with FDA Over Trial
With regulatory status of experimental in-vitro fertilization product in questions, company seeks resolution. Read More - Stepping with the Oldies
An off-the-shelf pedometer gives new depth to hospital data. Read More - Hospira Gains First Biosimilar Approval in EU
Therapeutic developed with Celltrion will compete with Remicade. Read More - Biogen Expands Antisense Bet with $100M Isis Deal
New long-term partnership deepens research ties and defines exclusive relationship. Read More
.gif)
